Reinhart Partners Has Lowered Its Astronics Com (ATRO) Position; Tenax Therapeutics (TENX) Sellers Increased By 25.1% Their Shorts

March 23, 2018 - By Michael Collier

Tenax Therapeutics Inc (NASDAQ:TENX) had an increase of 25.1% in short interest. TENX’s SI was 1.26M shares in March as released by FINRA. Its up 25.1% from 1.01M shares previously. With 478,300 avg volume, 3 days are for Tenax Therapeutics Inc (NASDAQ:TENX)’s short sellers to cover TENX’s short positions. The SI to Tenax Therapeutics Inc’s float is 5.77%. The stock decreased 7.82% or $0.6 during the last trading session, reaching $7.07. About 61,097 shares traded. Tenax Therapeutics, Inc. (NASDAQ:TENX) has declined 81.28% since March 23, 2017 and is downtrending. It has underperformed by 97.98% the S&P500.

Reinhart Partners Inc decreased Astronics Corp Com (ATRO) stake by 32.26% reported in 2017Q3 SEC filing. Reinhart Partners Inc sold 25,880 shares as Astronics Corp Com (ATRO)’s stock declined 11.89%. The Reinhart Partners Inc holds 54,339 shares with $1.62 million value, down from 80,219 last quarter. Astronics Corp Com now has $1.03B valuation. The stock decreased 5.37% or $2.07 during the last trading session, reaching $36.49. About 173,932 shares traded or 26.56% up from the average. Astronics Corporation (NASDAQ:ATRO) has risen 1.41% since March 23, 2017 and is uptrending. It has underperformed by 15.29% the S&P500.

Tenax Therapeutics, Inc., a specialty pharmaceutical company, focused on the identification, development, and commercialization of a portfolio of products for the critical care market in the United States and Canada. The company has market cap of $9.98 million. It focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome. It currently has negative earnings. The firm was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014.

Analysts await Astronics Corporation (NASDAQ:ATRO) to report earnings on May, 3. They expect $0.31 EPS, down 18.42% or $0.07 from last year’s $0.38 per share. ATRO’s profit will be $8.72 million for 29.43 P/E if the $0.31 EPS becomes a reality. After $0.41 actual EPS reported by Astronics Corporation for the previous quarter, Wall Street now forecasts -24.39% negative EPS growth.

Since January 19, 2018, it had 0 insider buys, and 10 selling transactions for $901,137 activity. The insider GUNDERMANN PETER J sold $86,960. 4,000 shares were sold by PEABODY MARK, worth $171,960.

Among 6 analysts covering Astronics Corporation (NASDAQ:ATRO), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Astronics Corporation had 21 analyst reports since August 6, 2015 according to SRatingsIntel. CL King initiated the shares of ATRO in report on Thursday, August 27 with “Buy” rating. The stock of Astronics Corporation (NASDAQ:ATRO) has “Hold” rating given on Friday, January 19 by SunTrust. SunTrust maintained the shares of ATRO in report on Monday, January 8 with “Hold” rating. As per Monday, September 26, the company rating was maintained by Canaccord Genuity. Canaccord Genuity maintained Astronics Corporation (NASDAQ:ATRO) on Friday, January 12 with “Buy” rating. As per Thursday, January 19, the company rating was initiated by SunTrust. Canaccord Genuity maintained the stock with “Buy” rating in Wednesday, August 16 report. The firm has “Buy” rating by Canaccord Genuity given on Thursday, August 3. The firm has “Overweight” rating by KeyBanc Capital Markets given on Wednesday, June 29. The firm has “Overweight” rating by KeyBanc Capital Markets given on Thursday, February 18.

Reinhart Partners Inc increased Gentex Corp Com (NASDAQ:GNTX) stake by 342,815 shares to 1.75 million valued at $34.61M in 2017Q3. It also upped Nexeo Solutions Inc Com Shs stake by 80,200 shares and now owns 464,990 shares. Citizens Finl Grp Inc Com (NYSE:CFG) was raised too.

Investors sentiment increased to 1.1 in Q3 2017. Its up 0.14, from 0.96 in 2017Q2. It increased, as 16 investors sold ATRO shares while 32 reduced holdings. 16 funds opened positions while 30 raised stakes. 18.18 million shares or 2.65% less from 18.67 million shares in 2017Q2 were reported. Bnp Paribas Arbitrage holds 6,954 shares or 0% of its portfolio. Legal & General Group Public Limited Company holds 5,619 shares or 0% of its portfolio. Nationwide Fund Advsr stated it has 13,239 shares or 0% of all its holdings. Deutsche State Bank Ag owns 81,292 shares. Mutual Of America Cap Limited Com has invested 0.05% of its portfolio in Astronics Corporation (NASDAQ:ATRO). Northern Tru Corporation, Illinois-based fund reported 325,777 shares. Great West Life Assurance Can has 1,984 shares. Invesco, Georgia-based fund reported 18,189 shares. Stoneridge Prns Limited Liability invested in 0.06% or 12,571 shares. 707,183 were reported by State Street Corp. Virginia Retirement Systems Et Al has 0.02% invested in Astronics Corporation (NASDAQ:ATRO). Ancora Advsr Ltd Llc reported 0.02% of its portfolio in Astronics Corporation (NASDAQ:ATRO). American Century invested in 30,763 shares. Victory Capital Mgmt owns 108,250 shares. Moreover, Goldman Sachs Gp has 0% invested in Astronics Corporation (NASDAQ:ATRO).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News